USE OF PROTEASOME INHIBITORS IN THE TREATMENT OF CORONAVIRUS INFECTIONS

USE OF PROTEASOME INHIBITORS IN THE TREATMENT OF CORONAVIRUS INFECTIONS

CLAIMS 1. A use of an oral formulation comprising a proteasome inhibitor for the prevention of SARS-CoV-2 infection in a mammal. 2. A use of an oral formulation comprising a proteasome inhibitor for the treatment of COVID-19 in a mammal. 3. A use of an oral formulation comprising a proteasome inhibi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: HNIK, PETER, CORMIER, STEPHANIA, ADER, ALLAN, CHO, TIFFANY, WASAN, KISHOR M, JELESIJEVIC, TOMISLAV, BRYLINSKI, MICHAL, ABRAMOV, JULIA, BESS, ADAM, GOULD, JANET, GRIGGS, NICHOLAS, MUKHOPADHYAY, SUPRATIK, GALLIANO, CHRIS, BERGLIND, FREJ KNUT GOSTA
Format: Patent
Sprache:eng ; fre
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:CLAIMS 1. A use of an oral formulation comprising a proteasome inhibitor for the prevention of SARS-CoV-2 infection in a mammal. 2. A use of an oral formulation comprising a proteasome inhibitor for the treatment of COVID-19 in a mammal. 3. A use of an oral formulation comprising a proteasome inhibitor for the prevention of the replication of the COVID-19 virus in mammalian cells. 4. The use according to any one of claims 1 to 3 where the proteasome inhibitor is bortezomib. 5. The use according to any one of claims 1 to 3 where the proteasome inhibitor is Carfilzomib. 6. The use according to any one of claims 1 to 3 where the proteasome inhibitor is Ixazomib. 21 Date Recue/Date Received 202 1-02-0 1